Cargando…

Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis

Objective To determine the association between exposure to radiotherapy for the treatment of prostate cancer and subsequent second malignancies (second primary cancers). Design Systematic review and meta-analysis of observational studies. Data sources Medline and Embase up to 6 April 2015 with no re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wallis, Christopher J D, Mahar, Alyson L, Choo, Richard, Herschorn, Sender, Kodama, Ronald T, Shah, Prakesh S, Danjoux, Cyril, Narod, Steven A, Nam, Robert K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775870/ https://www.ncbi.nlm.nih.gov/pubmed/26936410 http://dx.doi.org/10.1136/bmj.i851

Ejemplares similares

Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer
por: Wallis, C J D, et al.
Publicado: (2015)

The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation
por: Wallis, Christopher J. D., et al.
Publicado: (2018)

Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis
por: Wallis, Christopher J. D., et al.
Publicado: (2017)

Assessment of Secondary Sarcomas Among Patients With Cancer of the Abdomen or Pelvis Who Received Combinations of Surgery, Radiation, and Chemotherapy vs Surgery Alone
por: Hird, Amanda E., et al.
Publicado: (2020)

Complications after surgery for benign prostatic enlargement: a population-based cohort study in Ontario, Canada
por: Matta, Rano, et al.
Publicado: (2019)

Association between chronic bladder catheterisation and bladder cancer incidence and mortality: a population-based retrospective cohort study in Ontario, Canada
por: Hird, Amanda E, et al.
Publicado: (2021)

Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study
por: Matta, Rano, et al.
Publicado: (2020)

Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer
por: Chu, William, et al.
Publicado: (2015)

NIRS: Past, Present, and Future in Functional Urology
por: Koven, Alexander, et al.
Publicado: (2022)

A (relatively) risky business: the link between prostatic radiotherapy and second malignancies
por: Eyler, Christine E, et al.
Publicado: (2016)

Second Malignant Neoplasms Following Radiotherapy
por: Kumar, Sanath
Publicado: (2012)

Incidence of Second Malignancies for Prostate Cancer
por: Van Hemelrijck, Mieke, et al.
Publicado: (2014)

What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine
por: Wagg, Adrian S., et al.
Publicado: (2021)

Incidence and associated factors of developing second pelvic malignant neoplasms among prostate cancer patients treated with radiotherapy
por: Wang, Youbiao, et al.
Publicado: (2023)

Association of Radiotherapy for Rectal Cancer and Second Gynecological Malignant Neoplasms
por: Guan, Xu, et al.
Publicado: (2021)

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database
por: Chapple, Christopher R., et al.
Publicado: (2016)

Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
por: Herschorn, Sender, et al.
Publicado: (2020)

The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer
por: Akbari, M R, et al.
Publicado: (2014)

Second primary malignancy risk after radiotherapy in rectal cancer survivors
por: Wang, Ti-Hao, et al.
Publicado: (2018)

Carbon-ion radiotherapy in the treatment of radiation-induced second primary malignancies
por: Yang, Jing, et al.
Publicado: (2022)

Fusion in the ETS gene family and prostate cancer
por: Narod, S A, et al.
Publicado: (2008)

Radiotherapy of prostate cancer: impact of treatment characteristics on the incidence of second tumors
por: BUWENGE, Milly, et al.
Publicado: (2020)

Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy
por: Ng, Sweet Ping, et al.
Publicado: (2019)

Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma
por: Andersson, A, et al.
Publicado: (2008)

Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood.
por: de Vathaire, F., et al.
Publicado: (1989)

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
por: Staskin, David, et al.
Publicado: (2017)

Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy
por: Giannakeas, Vasily, et al.
Publicado: (2018)

The Effect of Age on Prostate Cancer Survival
por: Clark, Roderick, et al.
Publicado: (2022)

Overall survival and second primary malignancies in men with metastatic prostate cancer
por: Mehtälä, Juha, et al.
Publicado: (2020)

Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy.
por: Fosså, S. D., et al.
Publicado: (1990)

Second malignancies in breast cancer patients following radiotherapy: a study in Florence, Italy
por: Zhang, Wei, et al.
Publicado: (2011)

Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis
por: Hegemann, Nina-Sophie, et al.
Publicado: (2017)

The Risk of Second Primary Cancers in Prostate Cancer Survivors Treated in the Modern Radiotherapy Era
por: Jahreiß, Marie-Christina, et al.
Publicado: (2020)

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
por: Herschorn, Sender, et al.
Publicado: (2018)

Multiple therapeutic and preventive effects of 3,3′-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia
por: Zhang, William Weiben, et al.
Publicado: (2014)

Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)
por: Griebling, Tomas L., et al.
Publicado: (2020)

Prognostic Factors and Survival in Patients with Radiation-Related Second Malignant Neoplasms Following Radiotherapy for Nasopharyngeal Carcinoma
por: Xi, Mian, et al.
Publicado: (2013)

Risk of radiation-induced second malignant neoplasms from photon and proton radiotherapy in paediatric abdominal neuroblastoma
por: Taylor, Sophie, et al.
Publicado: (2021)

Quality of Life in Patients Treated with Palliative Radiotherapy for Advanced Lung Cancer and Lung Metastases
por: Koo, Kaitlin, et al.
Publicado: (2011)

Role of mpMRI of the prostate in screening for prostate cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fe4cucvdnmb19ojk0iehfb6l0g